Repligen Corporation [RGEN]
As of 2026-07-29 · framework v1.5.1
Catalyst Criteria is MEASURED. Time works for a long, so a dated event is not required to own a compounder. This calendar exists to confirm or refute the implied path, not to justify a position.
No date in this file is invented. Every hard date is quoted from a primary filing. Where Repligen has not announced a date, the row says so and gives the historical pattern separately, clearly labelled as a pattern and not a date.
| Date | Event | Source | Why it matters |
|---|---|---|---|
| 2026-08-06 | BioLife Solutions [BLFS] reports full Q2 2026 results | 8-K exh. 99.1, filed 2026-07-22: "BioLife plans to report its full second quarter 2026 financial results on August 6, 2026. Due to the pending acquisition, BioLife will not be hosting an earnings conference call." | First full look at the asset Repligen is buying at ~13.0x EV/Sales. Preliminary revenue $28.5m, +21% YoY. Tests the growth leg of the deal case. |
| 2026-12-18 | 2023 Notes become redeemable at Repligen's option | FY2025 10-K note 13: "The Company may redeem for cash, all or a portion of the 2023 Notes, at its option, on or after December 18, 2026 ... at a redemption price of 100% of the principal amount ... if certain conditions are met" | A capital-structure decision point inside the 12-month window, arriving immediately after ~$540m of cash leaves for BioLife. |
| 2026-12-18 | Only listed option expiry in the Dec-26/Jan-27 window | Alpaca chain, pulled 2026-07-29 | Total chain open interest 37 contracts. Recorded to document that no options expression exists, not as a tradeable event. |
| 2028-12-15 | $600.0m 1.00% Convertible Senior Notes mature | FY2025 10-K note 13: "The 2023 Notes will mature on December 15, 2028, unless earlier redeemed, repurchased or converted." Conversion price $203.06 — stock is 28.6% below. | Cash repayment obligation, outside the 12-month window but inside the 5-year implied path. |
| Window | Event | Source |
|---|---|---|
| Q4 2026 | BioLife acquisition expected to close | 8-K exh. 99.1, 2026-07-22: "The Transaction is expected to close in the fourth quarter of 2026, subject to customary regulatory approvals, approval by BioLife stockholders, and the satisfaction of other customary closing conditions." |
| Year one post-close | ≥$20m of synergies; ≥+5c adjusted EPS accretion | same |
| Year two post-close | ≥$30m of synergies; ≥+25c adjusted EPS accretion | same |
| Event | Status |
|---|---|
| Repligen Q3 2026 results | Not announced. Historical pattern only, not a date: 2025-10-28, 2024-11-12, 2023-10-31 — late October / early November. |
| Repligen Q4 / FY2026 results + FY2027 guidance | Not announced. Historical pattern only: 2026-02-24, 2025-02-20, 2024-02-21 — late February. |
| BioLife stockholder vote | Not set. Requires the S-4 registration statement / proxy, which had not been filed as of 2026-07-29. |
| HSR / regulatory clearance for BioLife | No date. Filing dates not disclosed. |
| Transformation Office programme milestones | No dates disclosed. Launched Q1 2026; site rationalisation, product-line margin optimisation, IT/AI investment. Costs are being excluded from adjusted earnings. |
The implied path requires 27.4% revenue CAGR. The 12-month target requires 12% organic growth and a re-rating from 10.15x to 11.0x EV/Sales. These events discriminate between them:
| Catalyst | Confirms the 12-month target if… | Refutes it if… |
|---|---|---|
| BLFS Q2, 2026-08-06 | Revenue ≥$28.5m confirmed, margin trajectory intact | Materially below the preliminary figure, or discontinued-ops noise larger than disclosed |
| Repligen Q3 2026 (unscheduled, late Oct/early Nov) | Organic growth ≥12% against a hardening comp; FY26 guide held or raised a third time | Organic below 9% — invalidation trigger #1 |
| Repligen Q3 2026 | Book-to-bill or an order figure reinstated | Seven more quarters of "order momentum" with nothing quantified |
| BioLife close, Q4 2026 | Closes on terms, ~6.6m shares issued, cash >$300m | Terms revised, cash mix raised, or the deal breaks |
| Converts, 2026-12-18 | Refinanced or left outstanding with cash cover intact | Called without a funding plan post-BioLife |
| FY2026 results, late Feb 2027 | FY2027 organic guide ≥12% including BioLife accretion | FY2027 guide below 10%, i.e. the recovery was a restock |
| FY2026 10-K Item 9A, late Feb 2027 (unscheduled) | ICFR reported effective — the IT-general-control and inventory-valuation material weaknesses remediated | A third consecutive year of ineffective ICFR, a new material weakness, or any further restatement — while integrating a $1.5bn acquisition |
The single highest-information event is Repligen's Q3 2026 release. It is the first quarter that carries a hardened comp (Q3 2025 was +18% reported), and it is the natural place for the order disclosure to return if management believes the order book supports the narrative. Its date has not been announced.